title: Responsiveness of the EuroQol EQ-5D and Hospital Anxiety and Depression Scale (HADS) in rheumatoid arthritis patients receiving tocilizumab.
abstract: The aim of this study was to assess the responsiveness to change of the quality of life evaluated by the EuroQol Five Dimensions Questionnaire (EQ-5D) and Hospital Anxiety and Depression Scale (HADS) after biological treatment in a population of rheumatoid arthritis patients. A cohort of patients with RA (n = 29) treated with tocilizumab (TCZ) were analyzed in the study. The inclusion criteria were patients aged between 18 and 65 years, fulfilling American College of Rheumatology 1987 criteria for RA. All patients had inadequate response to methotrexate and with no prior biologic exposure. They were evaluated clinically including Disease Activity Score 28 (DAS28), and the European Quality of Life 5 Dimensions (EQ-5D) to measure the quality of life, and HAD assessed the anxiety and depression status at the initiation of treatment with anti-IL 6 receptor antibody agent and after 6 months. Sensitivity to change was quantified by the effect size (ES) before and after the treatment with TCZ. Among 29 patients with RA included in the study, 25 were females and 4 males. The mean age was 42 years ± 13.4 (SD). Three patients were excluded from the study before 24 weeks because of serious side effects, and five have missing data. The study population exhibited significant decreases in all measures of disease activity at 24 weeks. Physical activity expressed by the Health Assessment Questionnaire (HAQ) score increased through the observation period (for all p < 0.001). Sensitivity to change was high for the VAS and EQ-5D (ES 1.58 and 1.36, respectively) but only moderate for the HAD anxiety component (ES = 0.70) and small for the HAD depression component (ES = 0.4). The EQ-5D and VAS were more responsive than HADS to evaluate the quality of life on patient with RA treated with TCZ.
authors.affiliation: Faculty of Medicine and Pharmacy, University Med V Souissi, Rabat-Sale, Morocco, leilatraki@yahoo.fr.
authors.forename: L
authors.initials: L
authors.lastname: Traki
authors.forename: S
authors.initials: S
authors.lastname: Rostom
authors.forename: L
authors.initials: L
authors.lastname: Tahiri
authors.forename: R
authors.initials: R
authors.lastname: Bahiri
authors.forename: T
authors.initials: T
authors.lastname: Harzy
authors.forename: R
authors.initials: R
authors.lastname: Abouqal
authors.forename: N
authors.initials: N
authors.lastname: Hajjaj-Hassouni
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000150:complications / Q000175:diagnosis*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy / Q000523:psychology*; D003863:Depression / Q000150:complications / Q000175:diagnosis*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D011788:Quality of Life / Q000523:psychology*; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C502936:tocilizumab
references.citation: Clin Rheumatol. 2012 Oct;31(10):1471-7
references.pmid: 22903698
references.citation: BMC Med Res Methodol. 2004 Apr 29;4:10
references.pmid: 15117417
references.citation: Heart. 2006 Jan;92(1):62-7
references.pmid: 15797936
references.citation: Acta Psychiatr Scand. 2010 Jan;121(1):71-4
references.pmid: 19681770
references.citation: J Psychosom Res. 2002 Feb;52(2):69-77
references.pmid: 11832252
references.citation: Acta Psychiatr Scand. 1983 Jun;67(6):361-70
references.pmid: 6880820
references.citation: Pain. 1994 Mar;56(3):289-297
references.pmid: 8022622
references.citation: Psychiatry Clin Neurosci. 2009 Feb;63(1):50-5
references.pmid: 19154212
references.citation: Qual Life Res. 2003 Feb;12(1):87-92
references.pmid: 12625521
references.citation: BMC Res Notes. 2012 Jan 22;5:56
references.pmid: 22264312
references.citation: J Eval Clin Pract. 2006 Oct;12(5):559-68
references.pmid: 16987118
references.citation: Int J Prev Med. 2013 Feb;4(2):218-25
references.pmid: 23543814
references.citation: Soc Psychiatry Psychiatr Epidemiol. 1995 Jan;30(1):26-31
references.pmid: 7892615
references.citation: Joint Bone Spine. 2003 Dec;70(6):509-14
references.pmid: 14667564
references.citation: Joint Bone Spine. 2002 May;69(3):300-6
references.pmid: 12102277
references.citation: Best Pract Res Clin Rheumatol. 2011 Aug;25(4):585-606
references.pmid: 22137926
references.citation: J Clin Epidemiol. 1997 Mar;50(3):239-46
references.pmid: 9120522
references.citation: Rheumatology (Oxford). 2012 Oct;51(10):1860-9
references.pmid: 22753773
references.citation: Health Qual Life Outcomes. 2013 Jan 10;11:3
references.pmid: 23305192
references.citation: BMC Musculoskelet Disord. 2009 Feb 07;10:18
references.pmid: 19200388
references.citation: Ann Saudi Med. 2009 Jul-Aug;29(4):304-8
references.pmid: 19584581
references.citation: Arthritis Care Res (Hoboken). 2012 Jun;64(6):826-32
references.pmid: 22262513
references.citation: Anesth Analg. 2005 Nov;101(5):1470-1476
references.pmid: 16244013
references.citation: BMC Med Res Methodol. 2008 Apr 25;8:26
references.pmid: 18439285
references.citation: Br J Psychiatry. 1987 Nov;151:687-8
references.pmid: 3446314
references.citation: BMC Psychiatry. 2012 Jan 24;12:6
references.pmid: 22269280
references.citation: Int J Technol Assess Health Care. 2006 Spring;22(2):235-41
references.pmid: 16571199
references.citation: Rheumatol Int. 2013 Feb;33(2):285-90
references.pmid: 22441961
references.citation: Qual Life Res. 2005 Jun;14(5):1401-6
references.pmid: 16047514
references.citation: Support Care Cancer. 2010 Oct;18(10):1279-86
references.pmid: 19941008